Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Ben Jenkins"'
Autor:
Robert Brown, Christina Yap, Johann De Bono, Malaka Ameratunga, Anna Minchom, Wei Yuan, Mateus Crespo, Bora Gurel, Ines Figueiredo, Susana Miranda, Ruth Riisnaes, Ana Ferreira, Claudia Bertan, Rita Pereira, Chloe Baker, Nina Tunariu, Suzanne Carreira, Udai Banerji, Juanita Lopez, Alison Turner, Wentin Chen, Abhijit Pal, Dionysis Papadatos-Pastos, Toby Prout, Maxime Chénard-Poirier, Andra Curcean, Nahal Masrour, Ricardo Morilla, Ben Jenkins, Anna Zachariou, Mona Parmar
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 6 (2022)
Externí odkaz:
https://doaj.org/article/b9a84246b2264ed1b2c2acbbf2f19d79
Publikováno v:
Philosophical Psychology. :1-27
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7b4d18421afa83711ec8039a463a8733
https://doi.org/10.1080/09515089.2023.2213245
https://doi.org/10.1080/09515089.2023.2213245
Autor:
Susana Banerjee, Vasiliki Michalarea, Joo Ern Ang, Alvaro Ingles Garces, Andrea Biondo, Ionut-Gabriel Funingana, Martin Little, Ruth Ruddle, Florence Raynaud, Ruth Riisnaes, Bora Gurel, Sue Chua, Nina Tunariu, Joanna C. Porter, Toby Prout, Mona Parmar, Anna Zachariou, Alison Turner, Ben Jenkins, Stuart McIntosh, Ed Ainscow, Anna Minchom, Juanita Lopez, Johann de Bono, Robert Jones, Emma Hall, Natalie Cook, Bristi Basu, Udai Banerji
Publikováno v:
Clinical Cancer Research. 28:4634-4641
Purpose: CT900 is a novel small molecule thymidylate synthase inhibitor that binds to α-folate receptor (α-FR) and thus is selectively taken up by α-FR–overexpressing tumors. Patients and Methods: A 3+3 dose escalation design was used. During do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5acc878b283c3c6e9cd5e46255c97453
https://doi.org/10.1158/1078-0432.ccr-22-1268
https://doi.org/10.1158/1078-0432.ccr-22-1268
Autor:
Udai Banerji, Bristi Basu, Natalie Cook, Emma Hall, Robert Jones, Johann de Bono, Juanita Lopez, Anna Minchom, Ed Ainscow, Stuart McIntosh, Ben Jenkins, Alison Turner, Anna Zachariou, Mona Parmar, Toby Prout, Joanna C. Porter, Nina Tunariu, Sue Chua, Bora Gurel, Ruth Riisnaes, Florence Raynaud, Ruth Ruddle, Martin Little, Ionut-Gabriel Funingana, Andrea Biondo, Alvaro Ingles Garces, Joo Ern Ang, Vasiliki Michalarea, Susana Banerjee
Supplementary Figure from A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2704c4994794b5ac32f8afd095444629
https://doi.org/10.1158/1078-0432.22489008
https://doi.org/10.1158/1078-0432.22489008
Autor:
Udai Banerji, Bristi Basu, Natalie Cook, Emma Hall, Robert Jones, Johann de Bono, Juanita Lopez, Anna Minchom, Ed Ainscow, Stuart McIntosh, Ben Jenkins, Alison Turner, Anna Zachariou, Mona Parmar, Toby Prout, Joanna C. Porter, Nina Tunariu, Sue Chua, Bora Gurel, Ruth Riisnaes, Florence Raynaud, Ruth Ruddle, Martin Little, Ionut-Gabriel Funingana, Andrea Biondo, Alvaro Ingles Garces, Joo Ern Ang, Vasiliki Michalarea, Susana Banerjee
Supplementary Table from A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0475121ba5d79aa5db6a42030c640f34
https://doi.org/10.1158/1078-0432.22488999
https://doi.org/10.1158/1078-0432.22488999
Autor:
Udai Banerji, Bristi Basu, Natalie Cook, Emma Hall, Robert Jones, Johann de Bono, Juanita Lopez, Anna Minchom, Ed Ainscow, Stuart McIntosh, Ben Jenkins, Alison Turner, Anna Zachariou, Mona Parmar, Toby Prout, Joanna C. Porter, Nina Tunariu, Sue Chua, Bora Gurel, Ruth Riisnaes, Florence Raynaud, Ruth Ruddle, Martin Little, Ionut-Gabriel Funingana, Andrea Biondo, Alvaro Ingles Garces, Joo Ern Ang, Vasiliki Michalarea, Susana Banerjee
Purpose:CT900 is a novel small molecule thymidylate synthase inhibitor that binds to α-folate receptor (α-FR) and thus is selectively taken up by α-FR–overexpressing tumors.Patients and Methods:A 3+3 dose escalation design was used. During dose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2962569a9f2efd37fe6e40c644a7cac
https://doi.org/10.1158/1078-0432.c.6532860
https://doi.org/10.1158/1078-0432.c.6532860
Autor:
Nicholas Turner, Claire Swift, Ben Jenkins, Lucy Kilburn, Maria Coakley, Matthew Beaney, Lisa Fox, Katie Goddard, Isaac Garcia-Murillas, Peter Hall, Catherine Harper-Wynne, Tamas Hickish, Sarah Kernaghan, Iain Macpherson, Alicia Okines, Carlo Palmieri, Sophie Perry, Katrina Randle, Claire Snowdon, Hilary Stobart, Andrew Wardley, Duncan Wheatley, Simon Waters, Matthew Winter, Judith Bliss
Publikováno v:
Cancer Research. 82:GS3-06
Background Detection of circulating tumour DNA (ctDNA) in patients (pts) who have completed treatment for early-stage triple negative breast cancer (TNBC) is associated with a very high risk of future relapse. Identifiying those at high risk of subse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c87025dfbe68a40c7a5f74097df5e6c8
https://doi.org/10.1158/1538-7445.sabcs21-gs3-06
https://doi.org/10.1158/1538-7445.sabcs21-gs3-06
Autor:
S. Shafiul Alam, Rojan Bhattarai, Tanveer Hussain, Vahan Gevorgian, Shahil Shah, Yaswanth Velaga, Matthew Roberts, Thomas Mosier, Jhair Alzamora, Ben Jenkins, Przemyslaw Koralewicz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fe749772252ba9c3b0e5730f58858ee9
https://doi.org/10.2172/1891110
https://doi.org/10.2172/1891110
Autor:
Dionysis Papadatos-Pastos, Wei Yuan, Abhijit Pal, Mateus Crespo, Ana Ferreira, Bora Gurel, Toby Prout, Malaka Ameratunga, Maxime Chénard-Poirier, Andra Curcean, Claudia Bertan, Chloe Baker, Susana Miranda, Nahal Masrour, Wentin Chen, Rita Pereira, Ines Figueiredo, Ricardo Morilla, Ben Jenkins, Anna Zachariou, Ruth Riisnaes, Mona Parmar, Alison Turner, Suzanne Carreira, Christina Yap, Robert Brown, Nina Tunariu, Udai Banerji, Juanita Lopez, Johann de Bono, Anna Minchom
Publikováno v:
Journal for ImmunoTherapy of Cancer. 10:e004495
BackgroundData suggest that immunomodulation induced by DNA hypomethylating agents can sensitize tumors to immune checkpoint inhibitors. We conducted a phase 1 dose-escalation trial (NCT02998567) of guadecitabine and pembrolizumab in patients with ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43f898adbd0ddda6a989472918aeaa25
https://doi.org/10.1136/jitc-2022-004495
https://doi.org/10.1136/jitc-2022-004495
Autor:
Udai Banerji, Christina Yap, Crescens Diane Tiu, Juanita Lopez, Ruth Riisnaes, Rob Daly, Ben Jenkins, Mateus Crespo, Anna Minchom, J. De-Bono, Suzanne Carreira, Igor Vivanco, Liam Welsh, Alison Turner, Anna Zachariou, Toby Prout, Timothy L. Jones, Bora Gurel, Nina Tunariu
Publikováno v:
Neuro Oncol
Aims Despite improved understanding of effector T-cell trafficking into the central nervous system, initial trials with anti-PD1/PD-L1 immune checkpoint inhibitors (ICIs) have failed to meet their primary endpoints. PTEN loss of function is frequent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d9da71cead53309992d0251f7330a9a
https://doi.org/10.1093/neuonc/noab195.022
https://doi.org/10.1093/neuonc/noab195.022